CHINA BETA THALASSEMIA REAL-WORLD STUDY FOR LUSPATERCEPT (THE ‘CHAMP’ STUDY)

CHINA BETA THALASSEMIA REAL-WORLD STUDY FOR LUSPATERCEPT (THE ‘CHAMP’ STUDY) - THE ‘CHAMP’ STUDY

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300071687

Enrollment

Unknown

Registered

2023-05-22

Start date

2023-05-29

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia

Interventions

Trail group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. =18 years of age at index date 2. Patients with the diagnosis of TD ß-thalassemia who are eligible to the treatment of luspatercept according to China’s prescribing label 3. Based on treating physician’s decision, patient who received luspatercept treatment (at least one dose) after its commercial launch 4. Patients receiving at least one shot of Luspatercept

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Transfusion burden of RBC units;Hemoglobin (Hb) level;	—

Secondary

Measure	Time frame
Adverse events;Reticulocyte count;Serum ferritin;Iron chelation therapy;Transfusion-free period;	—

Countries

China

Contacts

Public ContactJianPei Fang

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

jpfang2005@163.com+86 136 8229 0830

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026